Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Mar 7, 2013; 19(9): 1359-1371
Published online Mar 7, 2013. doi: 10.3748/wjg.v19.i9.1359
Published online Mar 7, 2013. doi: 10.3748/wjg.v19.i9.1359
Figure 1 Hepatocellular carcinoma rates in nucleos(t)ide analogs-naive cirrhotic patients with long-term response.
Several studies have shown that hepatitis B virus patients who achieve a virological response to lamivudine in some cases still develop hepatocellular carcinoma (HCC) as the only complication. LAM: Lamivudine; ETV: Entecavir; RCT: Randomized controlled trial.
- Citation: Della Corte C, Aghemo A, Colombo M. Individualized hepatocellular carcinoma risk: The challenges for designing successful chemoprevention strategies. World J Gastroenterol 2013; 19(9): 1359-1371
- URL: https://www.wjgnet.com/1007-9327/full/v19/i9/1359.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i9.1359